The retinopathy in diabetic patients is caused by diabetic microangiopathy and it results in blindness. A proliferative and a nonproliferative form can be distinguished.
Diabetic retinopathy is the most common cause for blindness in industrialized countries. About 10% of patients with insulin dependent diabetes type 2 develop retinopathy.
The determination of risk of complications is useful at the beginning of a disease process when strategy of diagnotic and therapy has to be scheduled.
It was demonstrated that the better is diabetes control the lower the risk of diabetic retinopathy. As progression of the disease can be reduced by proper treatment, the patients with diabetes require regular ophthalmological visits. A drug emerged (ranibizumab) suitable for treatment of macula oedema a variant of diabetic retinopathy.[Error: Macro 'ref' doesn't exist]
There is no explanation for the great difference in suceptibility to diabetic retinopathy. But there are still ongoing invertigations correlating retinopathy to genetic polymorphisms.
|Gestational diabetes mellitus|
|Hereditary susceptibility to diabetes|
|Neonatal diabetes mellitus|
|Noninsulin-dependent diabetes mellitus 1|
|Severe obesity and type 2 diabetes|
|Susceptibility to type 1 diabetes 01|
Kao YL et al. (1998) A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM.
Bahnsen U et al. (1992) A missense mutation in the vasopressin-neurophysin precursor gene cosegregates with human autosomal dominant neurohypophyseal diabetes insipidus.
Talbot C et al. (1994) Protection against Alzheimer's disease with apoE epsilon 2.
Corder EH et al. (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease.
Wikipedia articleWikipedia EN (Vasopressin)